Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)

Paul C Langley, PhD; Adjunct Professor, College of Pharmacy, University of Minnesota, Minneapolis MN

Abstract
Fundamental measurement is the basis for a rational assessment of patient reported outcome (PRO) value claims; both as response to therapy and the submission of credible and valuable value claims to formulary committees and other health system decision makers. It is important to emphasize the importance of creating interval and ratio scales as opposed to nominal and ordinal scales to support value claims; a recognition that follows from acceptance of conjoint simultaneous measurement and the contribution of Rasch or modern measurement theory (RMT). Failure to appreciate the role of RMT has led thousands of researchers simply to apply numerals to events, inappropriately applying the techniques of classical statistical analysis, with the result that all that is produced are ordinal PRO scores. Instead, we should be aiming for interval and ratio scores based on a comprehensible latent trait and the application of the Rasch model. The purpose of this brief commentary is to review the measurement properties of PRO value claims for mavacamten (Camzyos; Bristol Myers Squibb) in symptomatic hypertrophic cardiomyopathy (SHCM) and to judge whether they have any validity when judged against the requirements of modern measurement theory. The assessment includes both the recent evidence report by the Institute for Clinical and Economic Review (ICER) for mavacamten as well as pivotal randomized trial (RCT) value claims that combine clinical endpoints with PROs that fail the standards of fundamental evidence. These include the Kansas City Cardiomyopathy Questionnaire (KCCQ), the New York Heart Association (NYHA) functional classification and the EuroQuol EQ-5D-5L multiattribute health related quality of life (HRQoL) preference instrument. The review concludes that apart from purely clinical claims based on the various pivotal trials, there are no PRO claims for mavacamten in SHCM that meet the required measurement standards.

Keywords: Mavacamten, Camzyos, BMS, measurement failure, valueless claims, KCCQ, NYHA, EQ-5D-5L

INTRODUCTION
Meaningful value claims are critical to the review and acceptance of therapy interventions. Unfortunately, in health technology assessment, we face a major problem: none of the generic multiattribute measures that are commonly applied to support value claims, such as the EQ-5D-3L/5L and virtually none of the disease specific patient reported outcome (PRO) claims meet the required standards for fundamental measurement; they are valueless. The uncritical acceptance of these various PRO instruments over the past 30 or more years illustrates, unequivocally, the analytical dead end that has been the centerpiece of the health technology assessment belief system. This has been well documented but, to all intents and purposes, ignored; the belief system (or meme) continues to hold as witnessed by the endorsement of the latest defense of this belief system, the recently released Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) guide for submitting imaginary health economic evaluations. Although supported by some 15 journals, CHEERS 2022 is an analytical dead, notably in respect of its failure to recognize the standards of normal science and fundamental measurement.

Mavacamten (Camzyos; BristolMyersSquibb [BMS]) for symptomatic hypertrophic cardiomyopathy (SHCM) presents an instructive case study of the failure to recognize the constraints imposed by Rasch or modern measurement theory (RMT) on value claims; notably PROs. The purpose of this brief commentary is both to set out the limitations and, indeed, inadvisability of value claims that fail the required measurement standards for PROs and latent traits; pointing towards the need for a willingness to embrace RMT as the appropriate basis for positive and effective PRO response claims for mavacamten, an undeniably innovative product in SHCM.

MEASUREMENT AND FILTERS
If we are to capture a latent trait, with quality of life (QoL) as the prime example, then we must argue that the latent trait is actually measurable and that the resulting measure meets measurement standards for statistical analysis. In other words, measurement and the claim for a relevant measure must precede statistical evaluation. This is typically overlooked; mavacamten is unfortunately no exception. It is an error to apply numerals to events and assume that these standards apply; absent fundamental measurement.

The commitment to fundamental measurement to capture the patient voice is only met with simultaneous conjoint measurement; a fundamental measurement property introduced in the 1960s. If we accept the standards for fundamental measurement with conjoint simultaneous measurement for latent traits such a quality of life, then patient reported outcomes (PRO) claims can only be considered valid as it can be demonstrated that they have the desired ratio or interval properties. This requirement follows from the classification of scales of measurement: nominal, ordinal.
Interval and ratio. Each scale has one or more of the following properties: identity where each value has a unique meaning (nominal); magnitude where values on a scale have an ordered relationship with each other but the distance between each is unknown (nominal); invariance of comparison where scale units are equal in an ordered relationship with an arbitrary zero (interval scale); and a true zero (or a universal constant) where no value on the scale can take negative values (ratio); the ratio scale has the interval property. To these should be added the major contribution of conjoint simultaneous measurement to ensure that measurement in the social science for PROs matches the standards of the physical sciences. Applying RMT for PRO latent constrains or attributes creates, if feasible, an instrument or measure that combines the difficulty of PRO latent constrains or attributes creates, if feasible, an interval scale, not the ordinal scale that the EQ-5D-5L produces which cannot support therapy response claims.

Importantly, any notion that the ordinal multiattribute preference scores are ratio measures in disguise (a view held by ICER) must also be rejected; if for no other reason that there is no true zero as the various multiattribute algorithms, except the SF-6D, produce health states with negative scores. The EQ-5D-5L, for example, with US value weights, has an ordinal range from -0.573 to 1; this means that of the 3,125 health states defined by the symptoms and response levels (5^5) 625 or 20% have negative values. As detailed below for mavacamten, attempts to create value claims from the EQ-5D-5L instrument fail because the scale is ordinal. What is overlooked is that if a PRO interval scale is to be created you require Rasch conjoint simultaneous modeling for a coherent latent construct or attribute such as needs fulfillment quality of life (QoL). This measure will then support standard statistical techniques as an invariant interval scale, not the ordinal scale that the EQ-5D-5L produces which cannot support therapy response claims.

The failure to appreciate the necessary role of RMT in the evaluation of PRO instrument claims and other single attribute value claims means that prior to acceptance of a measure, which may be a pivotal phase 3 randomized clinical trial (RCT), both primary and secondary outcomes need to be evaluated for their concordance with the standards of fundamental measurement. In the case of mavacamten and heart disease claims for symptomatic hypertrophic cardiomyopathy (SHCM), the pivotal clinical trials include, apart from clinical end point measures for Normal Mixed Venous Oxygen Tension (pVO2) and Left Ventricular Outflow Tracy Time Integral (LVOT), both of which are single attribute and have the required unidimensional interval properties. Unfortunately, these measures are combined, in making the case for mavacamten with PRO measures that produce ordinal scores that cannot capture response to therapy. The EXPLORER-HCM trial (NCT03470545) includes four instruments as secondary endpoints which fail the required standards: the New York Heart Association (NYHA) questionnaire; the Kansas City Cardiomyopathy (KCCQ) questionnaire; the Hypertrophic Cardiomyopathy Symptoms Questionnaire (HCM SQ); and the EQ-5D-5L instrument. The VALOR-HCM trial (NCT04349072) includes as secondary endpoints the NYHA, KCCQ and NCMSQ, while the currently recruiting NCT05174416 trial in Chinese adults includes the NYHA and KCCQ questionnaires.

ASSUMPTION DRIVEN IMAGINARY CLAIMS

The manifest deficiencies of the reference modeling assumption driven simulations as the stock in trade of the
Institute for Clinical and Economic Review (ICER) are well established and have been reported on before in this Journal. They fail quite clearly the standards of normal science as well as those of fundamental measurement. The ICER report for mavacamten is clearly of no relevance to formulary decision making or pricing; it is a red herring. Emblematic of this lack of awareness of fundamental measurement is the place of the mathematically impossible QALY in ICER type models, a belief that the QALY has ratio properties that appears to be difficult to abandon. This false belief supports imaginary lifetime modeled claims for incremental cost per QALY and their application to cost-per-QALY thresholds to support pricing and formulary access recommendations. In the case of mavacamten, this model yields, in comparison to the standard of care for SHCM, an imaginary lifetime QALY improvement of 0.97 (from 12.54 to 13.51 QALYs) with cost-per-QALY fictional values of $893,000 versus standard of care and $1,100,000 versus disopyramide. Set against cost-per-QALY thresholds ranging from $100,000 to $150,000 per QALY gained, the ICER Health Benefit Price Benchmark, which apparently represents discounts or price premiums for a price range that for ICER aligns well with the treatment’s imaginary benefits to patients over their lifetimes, resulted for mavacamten in a recommended five-fold price reduction. This recommendation and the supporting analytical framework are clearly invalid. A conclusion, as demonstrated below, that will also hold whenever the basis for value claims relies upon preferences from generic multiattribute instruments such as the EQ-5D-5L.

**DISEASE SPECIFIC PATIENT REPORTED OUTCOMES CLAIMS**

A common feature of disease specific PRO value claims is the application of instrument scores that result from aggregating over the integer points of Likert scales. It has been recognized since the 1970s, at least among measurement theorists, that this simple process of aggregation is only valid if four conditions or assumptions are met: (i) that the Likert items and the proposed scale refer to a coherent and meaningful single attribute or latent construct; (ii) that all of the Likert items (or statements) are, from the prospective respondents perspective, of equal difficulty; (iii) that the thresholds between integer steps for each Likert item are of equal value or equal distance and (iv) that each Likert item has the same number of integer responses or thresholds. If these assumptions cannot be demonstrated then the ‘add em up’ procedure for the integer values yields only a multiattribute ordinal scale. Failing to meet these conditions ensures that Likert-based multiattribute PRO instruments with a single overall integer-based response score are clearly meaningless, and possibly misleading, as the basis for therapy response claims.

In heart disease, the KCCQ, with some 381 hits on PubMed (7 May, 2022) is a classic example of a Likert-based multiattribute instrument where response claims are pointless. The KCCQ comprises, in both its 23 and 12 item versions, Likert scales with both 5 and 6 integer response levels (4 and 5 thresholds respectively) for the Likert items; supposedly capturing 7 domains symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-sufficiency limitations. Each Likert item is scored from 0 – 100 with the overall integer score scaled from 0 to 100, and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent. Implicit assumption questions have never been raised or challenged, for a period now of almost 30 years; questions of fundamental measurement are absent. This categorization is meaningless.

The fact that the KCCQ clearly fails to meet the standards of fundamental measurement with RMT has not diminished its popularity, even in the case of the mavacamten EXPLORER-HCM trial. The KCCQ, in attempting to capture, presumably, seven latent attributes, means it cannot be modified ex post facto by application of the Rasch rating scale model (RSM). This relies on a coherent single attribute polytomous Likert structure, where attributes are analyzed and reported on individually; the KCCQ as an ordinal composite score over 7 domains simply fails. If these domains are considered key endpoints for a comparative evaluation of mavacamten then they should be reported on separately through application of the Rasch model with an instrument designed explicitly to capture the patient voice for each domain (or as instruments defined in terms of dichotomous or binary responses).

There have been extensive favorable assessments of the KCCQ 23/12 psychometric properties. These are, unfortunately, beside the point. Certainly, we can apply the tools of classical statistical analysis; but what is overlooked is that these assessments require prior application of the Rasch model to measure the attribute of interest. RMT stands out in being the only technique where data items are selected to fit the model. This produces an invariant interval measure that is the required input to a range of statistical evaluations, not ordinal data. RMT translate ordinal level data to interval data to support statistical analyses and to support claims for therapy impact. In the case of mavacamten this requirement for an internal measure is overlooked with the reporting in terms of the overall multiattribute ordinal KCCQ score with ‘improved’ symptom scores of +9.1 comparing 5.5 to 9.1 for the comparator and mavacamten respectively. As the KCCQ scores are ordinal, it is impossible to make any claims for comparative therapy impact on the health status of the target patient population; mean values are an impossible construct. If a blanket claim for improved health status is required there are two options: (i) to focus on a latent construct such as the single attribute need fulfillment quality of life, develop an instrument with dichotomous responses and transform the Rasch interval score to a bounded ratio scale which meets all required fundamental measurement standards or (ii) create a single attribute Likert polytomous data model and apply the recognized Rasch model to create the required interval measure. The dichotomous model is the preferred option with many examples of its
application in chronic disease states to support needs fulfillment quality of life claims.

A relevant instrument in heart disease that meets the required measurement standards is the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) developed some 15 years ago, with extensive applications (31 references for clinical trials) and 23 language versions²⁰.

The mavacamten EXPLORER-HCM trial also reports on therapy response defined as the proportion of patients who advance by at least one class in the NYHA. The NYHA is a symptom scale for the impact of systolic dysfunction based on four clinician assessed functional capacity classes: Class 1 – asymptomatic; Class 2 – symptoms with moderate exacerbations; Class 3 - symptoms with minimal exertion; and Class 4 – symptoms at rest. The NYHA is best considered as a Likert scale with fuzzy thresholds and an unknown psychometric distance between fuzzy classes; it is just a rule of thumb, subjective application of heart failure symptoms (with an emphasis on dyspnea). It has an adjunct role in clinical practice, but fails as a PRO scale with fundamental measurement to establish value claims for response to therapy. The NYHA has been subject considerable criticism over the past 30 years, not least because the classes are subjective with a failure to replicate claims across RCTs with similar protocols; indeed, physicians often find it difficult to assign patients to classes with many opting for multiple or bridging class assignment (e.g., class 2/3 or class 3/4).

The ICER modeling maps EQ-5D-3L utilities to NYHA classes to represent staging in heart failure response to mavacamten. Attempting to map one ordinal scale to another is clearly an impossible exercise; one which ignores completely the requirements of fundamental measurement²¹. This applies not only to the EQ-5D-3L/5L scales but also to mapping with the KCCQ ordinal scores. As an example, a recent paper assigned the KCCQ 80 plus (ordinal) score group (assumed to represent perfect health) to NYHA classes²². The comparison found that this KCCQ group comprised 24.4% of patients categorized as NYHA Class 1; 51.7% categorized as NYHA Class 2 and 18.9% categorized as NYHA Class 3. Given the subjective nature of any appraisal to reduce symptoms to a given class the obvious question is whether the thresholds between classes have any meaning – not only from the clinician’s perspective but, more importantly, the patient’s perspective in their subjective experience of heart failure; does a shift from class 2 to class 3 as assessed by the physician have any impact on the baselines needs fulfillment of the patient? Is it of interest to the patient? The EXPLORER-HCM trial claims that, as a response measure, that 34% more patients improved by at least one NYHA class compared to placebo. Unfortunately, as the psychometric distance between classes in unknown a blanket claim for moving between classes (or remaining in a class) has questionable validity. Given that EXPLORER-HCM covers the assignment of patients to both KCCQ and NYHA classes, it would be of interest to assess the extent to which claims for these matched each other for identical individuals, possibly qualifying overall separate PRO value claims for mavacamten against placebo. It is also worth noting that the primary endpoint for the EXPLORER-HCM trial was a composite of a clinical endpoint, a 1.5ml/kg per min or greater increase in pVO₂ and at least one NYHA class reduction or a 3.0ml/kg per min or greater improvement in pVO₂, and no worsening of NYHA class. As the NYHA classes are ordinal, lacking a common psychometric threshold distance, it is not clear how this would affect the overall primary value claim. The advice must be to focus only on the pVO₂ criterion as an interval measure that meets required measurement standards.

If the question is one of combining a clinical with a PRO measure to establish a primary endpoint, then the PRO must have invariant interval or ratio measurement properties. This excludes the ordinal KCCF, NYHA, HCSM-SoB and EQ-5D-5L scales. The solution is to ignore the physician as an intermediary to assign patients to NYHA classes but to use a needs fulfillment quality of life measure which is completed by the heart failure patient. This, developed with the tools of RMT will create both an invariant interval and a potential transformed bounded ratio scale which can then be combined with the pVO₂ to support valid claims for mavacamten primary outcome claims. As noted, there are many examples of RMT based needs fulfillment. One further example is the 20-item Psoriatic Arthritis Quality of Life Questionnaire (PSORIQoL), first developed in 2004 with some 60+ language versions and most recently translated to Brazilian Portuguese²³,²⁴. This is a binary-response interval cored RMT application, although it has yet to be transformed to a bounded ratio scale for needs-fulfillment QoL assessment.

The mavacamten EXPLORER-HCM protocol also proposes value claims based on a subdomain of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCSM-SoB); selecting four items that cover dyspnea²⁵. The items cover shortness of breath in the previous 24 hours for a 7-day period. Each item score is averaged over the 7 days to create a total sub-domain score in the range 0 – 18, with the lower score indicating less dyspnea. Once again, there is the constraint that the item scores are ordinal. As such they cannot be averaged or an overall score created and assessed with standard statistical techniques. The HCSM and HCSM-SoB suffer from the same limitations as the KCCQ; they cannot support value claims for mavacamten if the standards of Rasch measurement are recognized.

**EQ-5D-5L ORDINAL SCORES**

Assumption driven imaginary claims are, as noted above, the foundation for the current belief system or faith in health technology assessment modeling techniques for value claims. While it may seem odd that such claims should be taken seriously by health system decision makers, there is no doubt as to their acceptance both by academic groups, who are often consultants to ICER, and manufacturers. It could be argued that this reflects a lack of appreciation of the standards of normal
science, where value claims should be credible, evaluable and replicable, as well as a lack of understanding of RMT standards.

While the ICER simulation modelling focused on the EQ-5D-3L ordinal preference score to support the mathematically impossible QALYs, the EXPLORER-HCM mavacamten study has based comparative value claims based on the EQ-5D-5L ordinal instrument scores; this analysis is fatally flawed because there was no understanding that the EQ-5D-5L preference scores are ordinal. This is a composite score that lacks unidimensionality, attempting to bundle a set of five symptoms each defined in terms of ordinal five level responses (i.e., the distance between the response levels is unknown). The difference between the two EQ-5D variants lies in the response levels (five) for the same symptom set; they also produce quite different scores for similar health states. Unfortunately, the 5L version suffers from the same fatal flaws as the 3L version of the EQ-5D family. First, the value claims expressed as preferences are not invariant single attribute interval measures only multiattribute ordinal scores. Second, the preferences are a composite bundle of symptoms, each of which is reported on an ordinal scale; for bundles to be ‘aggregated’ each has to have ratio measurement properties. This is not the case with the EQ-5D-5L scoring algorithm. Third, the EQ-5D-5L cannot have ratio properties because it lacks a true zero. Lacking a true zero and invariance of comparisons means that the scale is ordinal. It cannot support measures of mean values, standard deviations or comparisons over time (in this case baseline to 30 weeks); the analysis presented is therefore a wasted effort. Fourth, the EQ-5D-5L scale can only support non-parametric statistics; it cannot support claims for response to therapy, only changes in rank orderings, or comparisons with other scales. Finally, considering the role of a single attribute QoL latent construct, the EQ-5D-5L is only an ordinal composite multidimensional health-related quality of life measure (HRQoL). HRQoL claims fail to capture the patient voice by evaluating clinician determined generic symptoms defined to represent clinically defined quality of life rather than a latent measure such as needs-fulfillment quality of life. Capturing both needs difficulty and patient response ability in a single attribute interval scale, and in some cases a bounded ratio scale. This is the only acceptable basis for PRO preference value claims.

It should be noted that the EQ-5D-5L is not alone among multiattribute instruments. The same arguments apply to the Health Utilities Index (Mk1/2) and the standard gamble and time trade off measures. They all attempt to value a composite bundle of clinical attributes and can produce negative scores. The principal flaw is the same as the EQ-5D-5L: no thought was given in development to the required measurement properties of the instrument with single unidimensional attributes and empirically evaluable ratio properties.

Ex post facto, a multiattribute HRQoL ordinal scale cannot be transformed to a single attribute, unidimensional scale with a true zero and interval properties. In common with the visual analogue scale (VAS) it lacks invariance of comparisons; for a VAS scale representing distances between fractions or percentages, we need to capture the property of relative difference. The VAS must be transformed from an ordinal to an interval scale by a natural log odds application; a key step in Rasch measurement modeling1.

CONCLUSIONS

Although mavacamten is not alone in failing to appreciate the importance and constraints imposed by fundamental measurement, it is salutary to conclude that none of the various PRO measures proposed as value claims or as elements in a value claim have any merit as value claims for comparative therapy response. The various mavacamten clinical trials fail to provide any surety for PRO claims: the NYHA functional classification, the KCCQ scale, the HCMSQ-SoB scale and the EQ-5D-5L. Judged by RMT standards the KCCQ does not capture quality of life as a specific domain; a major shortcoming for QoL claims. While the clinical claims meet the required standards (LVOT gradient and pVO2), combining the pPVO2 with an ordinal scale to support primary outcome claims is clearly problematic. It would have been preferable to focus only on the clinical endpoints. Add to this, of course, the ICER assumption driven simulation which is designed to create only imaginary (and non-evaluable) claims for QALY’s, incremental cost-per-QALY claims, QALY thresholds and an overall and imaginary claim for the pricing point likelihood of cost-effectiveness, with probabilistic sensitivity analysis. The ICER modeling and associated recommendations are an analytical dead end.

If a formulary submission to meet the standards for normal science and fundamental measurement then claims by BMS for mavacamten should put to one side the present mix of PRO claims, focusing on clinical endpoints that have the required measurement properties; noting the inadvisability of combining inappropriate PRO measures with clinical measures. If QoL is considered a latent construct of importance in assessing the extent to which mavacamten can contribute to meeting patient need in SHCM, then there is the option of developing an instrument specific to the target SHCM population. There are presumably, proposed RCTs and observational studies where such an instrument this could be applied.

In the case of mavacamten, the trial results can support purely clinical claims; but that is as far as it goes. The patient voice is absent with no possibility of value claims for quality of life that meet requirements. A research program to discover new, yet provisional facts to support claims for QoL cannot succeed if the intellectual tools applied are unfit for the task. On a positive note, however, is the fact that we have the tools (and have had for many decades) to apply the required measurement standards to support PRO quality of life needs fulfillment value claims in heart disease and across the board for chronic conditions.
Conflicts of Interest: PCL is an Advisory Board Member and Consultant to the Institute for Patient Access and Affordability, a program of Patients Rising.

Note: The opinions contained in this paper are those of the author (PCL)

REFERENCES

1. Bond T, Yan Z, Heene M. Applying the Rasch Model: Fundamental Measurement in the Human Sciences (4th Ed.). New York: Routledge; 2021

2. Husereau D, Drummond M, Augustovski F et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022; 25: 10-31

3. Langley P. Nothing to Cheer About: Endorsing Imaginary Economic Evaluations and Value Claims with CHEERS 22 [version 1; peer review: 2 approved] F1000Research 2022, 11:248

4. McKenna S, Heaney A, Langley P. Fundamental Outcome Measurement: Selecting Patient Reported Outcome Instruments and Interpreting the Data they Produce. InovPharm. 2021; 12(2): No. 17

5. Rasch G. Probabilistic models for some intelligence and attainment tests. Copenhagen: Danmarks Paedagogiske, Institut, 1960

6. Luce R, Tukey J. Simultaneous Conjoint Measurement: A new type of fundamental measurement. J Math Psychol. 1964;1(1):1-27

7. Langley P. McKenna S. Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure. InovPharm. 2021;12(2): No. 6

8. Langley P. The New Start Formulary Submission and Evaluation Guidelines for Value Claims with Pharmaceutical Products and Devices. Version 2.0 May 2022. https://maimonresearch.com/category/formulary-submissions

9. Langley P, McKenna S. Measurement modeling and QALYs [version 1; peer review 2 approved]. F1000 Research, 9:1048

10. Langley P. The Great I-QALY Disaster. InovPharm. 2020; 11(3): No 7

11. Pickard A, Law E, Jiang R et al. United States valuation of EQ-5D-5L health states using an international protocol. ValueHealth, 2019;22(8):93141

12. Xie J, Wang Y, Xu Y et al. Assessing health-related quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-5L – based utilities in the EXPLORER-HCM trial. J Med Econ. 2022; 25(1):51-58

13. McKenna SP, Heaney A. Setting and maintaining standards for patient-reported outcome measures: Can we rely on the COSMIN checklists? J Med Econ. 2021;24(1):502–511

14. Langley P. Nonsense on Stilts – Part 1: The ICER 2020-2023 value assessment framework for constructing imaginary worlds. InovPharm. 2020;11(1):No. 12

15. Wasfy J, Walton S, Beinfeld M et al. Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value; Evidence Report. Institute for Clinical and Economic Review, October 7, 2021.

16. Langley P. Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment. InovPharm. 2021; 12(2): No.20

17. Spertus J, Jones P, Sandhu A et al. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care. J Am College Cardiology. 2020;76(2)

18. Spertus J, Fine J, Elliott et al. Mavacamten for treatment of symptomatic hypertrophic cardiomyopathy (EXPLORER – HCM): A health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet.2021;397(10293):2467-2475
19 Olivotto I, Oreziak A, Barriales-Villa R et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomized, double-blind, placebo controlled, phase 3 trial. *Lancet*; 2020;396(10253):750-69

20 McKenna S, Doughty N, Meads D, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health related quality of life for patients with pulmonary hypertension. *Qual Life Res*. 2006;15(1):103-15

21 Langley P. Mapping Impossible Utilities: The ICER report on Tezepelumab for Severe Asthma. *InovPharm*. 2022:13(2): No.1

22 Tran A, Cham P, Jones P et al. Comparison of patient self-reported health status with clinician assigned New York Health Association classification. *JAMA Network Open*. 2020;3(8)

23 McKenna S, Doward L, Whalley D et a. Development of the PSORIQoL; A quality of life instrument specific to psoriatic arthritis. *Ann Rheum Dis*. 2004;63(2):162-0

24 Goncalves R, Heaney A, McKenna S et al. Psoriatic Arthritis Quality of Life Questionnaire: translation, cultural adaptation and validation into Brazilian Portuguese language. *Advances Rheumatology*. 2021;61{13

25 Zaiser E, Sehnert A, Duenas A et al. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. *J Patient Reported Outcomes*; 2020;; 4(102)